Lexeo Therapeutics, Inc.
LX2006
Friedreich ataxia (FA) cardiomyopathy
Countdown
542days
Phase 2 readout · ~ Dec 31, 2027 estimated
What's at stake
Phase 2 trial results for LX2006 in Friedreich ataxia (FA) cardiomyopathy are due ~ Dec 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Lexeo expects a topline data readout in the second half of 2027 and a BLA submission under the accelerated approval pathway in the first half of 2028.”